The bladder is easy to overlook—until it starts causing trouble. This small, balloon-like organ in the lower urinary tract quietly stores and releases urine, helping the body eliminate waste and ...
The FDA accepted an application for Padcev plus Keytruda for patients with muscle-invasive bladder cancer ineligible for ...
Enfortumab vedotin and pembrolizumab with surgery significantly improve outcomes in cisplatin-ineligible MIBC patients, ...
Inlexzo is supplied as a single-dose intravesical system containing 225mg of gemcitabine plus a sterile urinary catheter and stylet.
Results presented by AstraZeneca from its phase 3 trial of Imfinzi in patients with high-risk, non-muscle invasive bladder ...
EG110A received FDA fast track designation to treat neurogenic detrusor overactivity, a bladder issue common in MS.
Tecentriq reduced the risk of death by 41% and the risk of disease recurrence or death by 36% compared with placebo –– ...
FDA prioritizes review of enfortumab vedotin and pembrolizumab for muscle-invasive bladder cancer, showing promising results in reducing recurrence and mortality.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback